Peter Reichardt, MD, PhD, on GIST: Adjuvant Imatinib for High-Risk Disease

June 22, 2020 By The ASCO Post Staff

Peter Reichardt, MD, PhD, of Helios Klinikum Berlin-Buch, discusses the 10-year survival analysis of 3 years vs 1 year of adjuvant imatinib for patients with high-risk gastrointestinal stromal tumor. The study found that about 50% of deaths can be avoided with longer imatinib treatment (Abstract 11503).

Related Content